Unraveling the role of proteases in cancer

Clinica Chimica Acta

Volumn 291, Issue 2, 2000, Pages 113-135

  Koblinski, Jennifer E ^a   Ahram, Mamoun ^a   Sloane, Bonnie F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cathepsin B; Proteases; Tumor invasion; Tumor progression; Tumor stromal interactions

Indexed keywords

CATHEPSIN B; PROTEINASE;

CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; ENZYME ACTIVITY; ENZYME ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL;

EID: 0034651996     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00224-7     Document Type: Article

References (146)

1. Liotta L.A., Rao C.N., Barsky S.H. Tumor invasion and the extracellular matrix. Lab Invest. 49:1983;636-649.
2. Escot C., Zhao Y., Puech C., Rochefort H. Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer. Breast Cancer Res Treat. 38:1996;217-226.
3. Hildenbrand R., Glienke W., Magdolen V., Graeff H., Stutte H.J., Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 110:1998;27-32.
4. Castiglioni T., Merino M.J., Elsner B., Lah T.T., Sloane B.F., Emmert-Buck M.R. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol. 25:1994;857-862.
5. Nakopoulou L., Giannopoulou I., Gakiopoulou H., Liapis H., Tzonou A., Davaris P.S. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol. 30:1999;436-442.
6. Ueno H., Nakamura H., Inoue M., et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57:1997;2055-2060.
7. Christensen L., Wiborg Simonsen A.C., Heegaard C.W., et al. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer. 66:1996;441-452.
8. McDonnell S., Navre M., Coffey R.J. Jr., Matrisian L.M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 4:1991;527-533.
9. Pyke C., Kristensen P., Ralfkiaer E., et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 138:1991;1059-1067.
10. Ohtani H., Motohashi H., Sato H., Seiki M., Nagura H. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer. 68:1996;565-570.
11. Campo E., Munoz J., Miquel R., et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 145:1994;301-309.
12. Mayer A., Fritz E., Fortelny R., Kofler K., Ludwig H. Immunohistochemical evaluation of cathepsin D expression in colorectal cancer. Cancer Invest. 15:1997;106-110.
13. Poulsom R., Pignatelli M., Stetler-Stevenson W.G., et al. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 141:1992;389-396.
14. Sato T., Nishimura G., Yonemura Y., et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology. 52:1995;347-352.
15. Ohtani H., Pyke C., Dano K., Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer. 62:1995;691-696.
16. Nielsen B.S., Sehested M., Timshel S., Pyke C., Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest. 74:1996;168-177.
17. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 149:1996;273-282.
18. Schwartz-Albiez R., Koretz K., Moller P., Wirl G. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells. Differentiation. 52:1993;229-237.
19. Grondahl-Hansen J., Ralfkiaer E., Kirkeby L.T., Kristensen P., Lund L.R., Dano K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol. 138:1991;111-117.
20. Joensuu H., Toikkanen S., Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer. 71:1995;155-159.
21. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1997;1260-1270.
22. Noel A., Gilles C., Bajou K., et al. Emerging roles for proteinases in cancer. Invasion Metastasis. 17:1997;221-239.
23. Kim J., Yu W., Kovalski K., Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 94:1998;353-362.
24. Koop S., Khokha R., Schmidt E.E., MacDonald I.C., Morris V.L., Chambers A.F. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54:1994;4791-4797.
25. Sympson C.J., Bissell M.J., Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol. 6:1995;159-163.
26. Wilson C.L., Heppner K.J., Labosky P.A., Hogan B.L., Matrisian L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA. 94:1997;1402-1407.
27. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M.J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 139:1997;1861-1872.
28. Rochefort H., Liaudet-Coopman E. Cathepsin D in cancer metastasis: a protease and a ligand. APMIS. 107:1999;86-95.
29. Poole A.R., Tiltman K.J., Recklies A.D., Stoker T.A.M. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature. 273:1978;545-547.
30. Watanabe M., Higashi T., Watanabe A., Osawa T., Sato Y., Kimura Y., Tominaga S., Hashimoto N., Yoshida Y., Morimoto S., Shito S., Hasinoto M., Kobayashi M., Tomoda J., Tsuji T. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings. Biochem Med Metab Biol. 42:1989;21-29.
31. Sukoh N., Abe S., Ogura S., et al. Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer. 74:1994;46-51.
32. Sinha A.A., Wilson M.J., Gleason D.F., Reddy P.K., Sameni M., Sloane B.F. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate. 26:1995;171-178.
33. Rempel S.A., Rosenblum M.L., Mikkelsen T., et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54:1994;6027-6031.
34. Sloane B.F., Dunn J.R., Honn K.V. Lysosomal cathepsin B: correlation with metastatic potential. Science. 212:1981;1151-1153.
35. Page A.E., Warburton M.J., Chambers T.J., Pringle J.A., Hayman A.R. Human osteoclastomas contain multiple forms of cathepsin B. Biochim Biophys Acta. 1116:1992;57-66.
36. Berquin I.M., Yan S.-Q., Huang L., Sloane B.F., Troen B.R. Differentiating agents regulate cathepsin B gene expression in HL-60 cells. J Leukocyte Biol, in press.
37. Berquin I.M., Cao L., Fong D., Sloane B.F. Identification of two new exons and multiple transcription start points in the 5′-untranslated region of the human cathepsin-B-encoding gene. Gene. 159:1995;143-149.
38. Fong D., Chan M.M., Hsieh W.T., Menninger J.C., Ward D.C. Confirmation of the human cathepsin B gene (CTSB) assignment to chromosome 8. Hum Genet. 89:1992;10-12.
39. Hughes S.J., Glover T.W., Zhu X.X., et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA. 95:1998;12410-12415.
40. Abdollahi A., Getts L.A., Sonoda G., et al. Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J Soc Gynecol Investig. 6:1999;32-40.
41. Shuja S., Murnane M.J. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int J Cancer. 66:1996;420-426.
42. Sloane B.F., Moin K., Sameni M., Tait L.R., Rozhin J., Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci. 107:1994;373-384.
43. Rozhin J., Sameni M., Ziegler G., Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 54:1994;6517-6525.
44. Sloane B.F., Rozhin J., Johnson K., Taylor H., Crissman J.D., Honn K.V. Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci USA. 83:1986;2483-2487.
45. Sameni M., Elliott E., Ziegler G., Fortgens P.H., Dennison C., Sloane B.F. Cathepsin B and D are localized at the surface of human breast cancer cells. Path Oncol Res. 1:1995;43-53.
46. Kassam G., Le B.H., Choi K.S., et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of tPA-dependent plasminogen activation. Biochemistry. 37:1998;16958-16966.
47. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 269:1994;21191-21197.
48. Schnitzer J.E., Liu J., Oh P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J Biol Chem. 270:1995;14399-14404.
49. Stan R.V., Roberts W.G., Predescu D., et al. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell. 8:1997;595-605.
50. Stahl A., Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 129:1995;335-344.
51. Kobayashi H., Schmitt M., Goretzki L., et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 266:1991;5147-5152.
52. Kobayashi H., Moniwa N., Sugimura M., Shinohara H., Ohi H., Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta. 1178:1993;55-62.
53. Visscher D.W., Sloane B., Sakr W., et al. Clinicopathologic significance of cathepsin B and urokinase-type plasminogen activator immunostaining in colorectal adenocarcinoma. Intl J Surg Pathol. 1:1994;227-234.
54. Van der Stappen J.W.J., Williams A.C., Maciewicz R.A., Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer. 67:1996;547-554.
55. Dalet-Fumeron V., Guinec N., Pagano M. In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett. 332:1993;251-254.
56. Dalet-Fumeron V., Boudjennah L., Pagano M. Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator. Arch Biochem Biophys. 335:1996;351-357.
57. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 44:1985;139-266.
58. He C.S., Wilhelm S.M., Pentland A.P., et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci. 86:1989;2632-2636.
59. Matrisian L.M., Bowden G.T. Stromelysin/transin and tumor progression. Semin Cancer Biol. 1:1990;107-115.
60. Baramova E.N., Bajou K., Remacle A., et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 405:1997;157-162.
61. Festuccia C., Guerra F., D'Ascenzo S., Giunciuglio D., Albini A., Bologna M. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer. 75:1998;418-431.
62. Carmeliet P., Moons L., Lijnen R., et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 17:1997;439-444.
63. Eeckhout Y., Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B., plasmin and kallikrein, and spontaneous activation. Biochem J. 166:1977;21-31.
64. Murphy G., Ward R., Gavrilovic J., Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix Suppl. 1:1992;224-230.
65. Suzuki K., Enghild J.J., Morodomi T., Salvesen G., Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 29:1990;10261-10270.
66. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 274:1999;13066-13076.
67. Van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res. 50:1988;159-196.
68. Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int. 48:1998;1-9.
69. Bissell M.J., Weaver V.M., Lelievre S.A., Wang F., Petersen O.W., Schmeichel K.L. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 59:1999;1757ss-1763s. discussion 1763s-1764s.
70. Gatenby R.A., Seftor E.A., Hendrix M.J.C. Fibroblast enhancement of tumor invasion in a tumor-host interface recapitulated in-vitro. Pathol Oncol Res. 2:1996;151-156.
71. Himelstein B.P., Canete-Soler R., Bernhard E.J., Muschel R.J. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci. 107:1994;477-486.
72. Borchers A.H., Powell M.B., Fusenig N.E., Bowden G.T. Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures. Exp Cell Res. 213:1994;143-147.
73. Noel A.C., Polette M., Lewalle J.M., et al. Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int J Cancer. 56:1994;331-336.
74. Uria J.A., Stahle-Backdahl M., Seiki M., Fueyo A., Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 57:1997;4882-4888.
75. Bechtel M.J., Reinartz J., Rox J.M., Inndorf S., Schaefer B.M., Kramer M.D. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha. Exp Cell Res. 223:1996;395-404.
76. Esteve P.O., Tremblay P., Houde M., St-Pierre Y., Mandeville R. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta. 1403:1998;85-96.
77. Basset P., Bellocq J.P., Wolf C., et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348:1990;699-704.
78. Cavailles V., Garcia M., Rochefort H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol. 3:1989;552-558.
79. Ward C.J., Crocker J., Chan S.J., Stockley R.A., Burnett D. Changes in the expression of elastase and cathepsin B with differentiation of U937 promonocytes by GMCSF. Biochem Biophys Res Commun. 167:1990;659-664.
80. Graf M., Baici A., Strauli P. Histochemical localization of cathepsin B at the invasion front of the rabbit V2 carcinoma. Lab Invest. 45:1981;587-596.
81. Baici A., Gyger-Marazzi M., Strauli P. Extracellular cysteine proteinase and collagenase activities as a consequence of tumor-host interaction in the rabbit V2 carcinoma. Invasion Metastasis. 4:1984;13-27.
82. Baici A., Knopfel M., Keist R. Tumor-host interactions in the rabbit V2 carcinoma: stimulation of cathepsin B in host fibroblasts by a tumor-derived cytokine. Invasion Metastasis. 8:1988;143-158.
83. Visscher D.W., Sloane B.F., Sameni M., Babiarz J.W., Jacobson J., Crissman J.D. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod Pathol. 7:1994;76-81.
84. Emmert-Buck M.R., Roth M.J., Zhuang Z., et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol. 145:1994;1285-1290.
85. Sinha A.A., Gleason D.F., Deleon O.F., Wilson M.J., Sloane B.F. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec. 235:1993;233-240.
86. Li Q., Bever C.T. Jr. Effect of protein kinase modulators on the regulation of cathepsin B activity in THP-1 human monocytic leukemia cells. Oncol Rep. 5:1998;227-233.
87. Huet G., Flipo R.M., Colin C., et al. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 36:1993;772-780.
88. Boudreau N., Werb Z., Bissell M.J. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc Natl Acad Sci USA. 93:1996;3509-3513.
89. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1996;1069-1078.
90. Adams J.C., Watt F.M. Regulation of development and differentiation by the extracellular matrix. Development. 117:1993;1183-1198.
91. Underwood P.A., Bean P.A., Whitelock J.M. Inhibition of endothelial cell adhesion and proliferation by extracellular matrix from vascular smooth muscle cells: role of type V collagen. Atherosclerosis. 141:1998;141-152.
92. Fridman R., Giaccone G., Kanemoto T., Martin G.R., Gazdar A.F., Mulshine J.L. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA. 87:1990;6698-6702.
93. Sonohara S., Mira-y-Lopez R., Brentani M.M. Laminin and estradiol regulation of the plasminogen-activator system in MCF-7 breast-carcinoma cells. Int J Cancer. 76:1998;77-85.
94. Mauch C., Adelmann-Grill B., Hatamochi A., Krieg T. Collagenase gene expression in fibroblasts is regulated by a three-dimensional contact with collagen. FEBS Lett. 250:1989;301-305.
95. Bafetti L.M., Young T.N., Itoh Y., Stack M.S. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem. 273:1998;143-149.
96. Stanton H., Gavrilovic J., Atkinson S.J., et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci. 111:1998;2789-2798.
97. Corcoran M.L., Kibbey M.C., Kleinman H.K., Wahl L.M. Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases. J Biol Chem. 270:1995;10365-10368.
98. Singhal P.C., Franki N., Kumari S., Sanwal V., Wagner J.D., Mattana J. Extracellular matrix modulates mesangial cell apoptosis and mRNA expression of cathepsin-B and tissue transglutaminase. J Cell Biochem. 68:1998;22-30.
99. Chopra H., Timar J., Chen Y.Q., et al. The lipoxygenase metabolite 12(S)-HETE induces a cytoskeleton-dependent increase in surface expression of integrin alpha IIb beta 3 on melanoma cells. Int J Cancer. 49:1991;774-786.
100. Honn K.V., Timar J., Rozhin J., et al. A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res. 214:1994;120-130.
101. Langholz O., Rockel D., Mauch C., et al. Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. J Cell Biol. 131:1995;1903-1915.
102. Xu J., Clark R.A. A three-dimensional collagen lattice induces protein kinase C-zeta activity: role in alpha2 integrin and collagenase mRNA expression. J Cell Biol. 136:1997;473-483.
103. Buck M.R., Karustis D.G., Day N.A., Honn K.V., Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 282:1992;273-278.
104. Lah T.T., Buck M.R., Honn K.V., et al. Degradation of laminin by human tumor cathepsin B. Clin Exp Metastasis. 7:1989;461-468.
105. Khan A., Krishna M., Baker S.P., Malhothra R., Banner B.F. Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch Pathol Lab Med. 122:1998;172-177.
106. Khan A., Krishna M., Baker S.P., Banner B.F. Cathepsin B and tumor-associated laminin expression in the progression of colorectal adenoma to carcinoma. Mod Pathol. 11:1998;704-708.
107. Griffiths J.R. Are cancer cells acidic? Br J Cancer. 64:1991;425-427.
108. Montcourrier P., Silver I., Farnoud R., Bird I., Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis. 15:1997;382-392.
109. Baron R. Molecular mechanisms of bone resorption by the osteoclast. Anat Rec. 224:1989;317-324.
110. Coopman P.J., Thomas D.M., Gehlsen K.R., Mueller S.C. Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell. 7:1996;1789-1804.
111. Montcourrier P., Mangeat P.H., Salazar G., Morisset M., Sahuquet A., Rochefort H. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res. 50:1990;6045-6054.
112. Montcourrier P., Mangeat P.H., Valembois C., et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. Cell Sci. 107:1994;2381-2391.
113. Roger P., Montcourrier P., Maudelonde T., et al. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol. 25:1994;863-871.
114. Kramer R.H., Bensch K.G., Wong J. Invasion of reconstituted basement membrane matrix by metastatic human tumor cells. Cancer Res. 46:1986;1980-1989.
115. Masson R., Lefebvre O., Noel A., et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 140:1998;1535-1541.
116. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 247:1990;322-324.
117. Su L.K., Kinzler K.W., Vogelstein B., et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 256:1992;668-670.
118. Dufek V., Jirasek V., Kral V., Matous B., Drazna E. Changes in serum cathepsin B-like activity in patients with colorectal cancer. Neoplasma. 32:1985;51-54.
119. Satoh Y., Higashi T., Nouso K., et al. Cathepsin B in the growth of colorectal cancer: suppressive effect of leupeptin on the growth of DMH-induced rat colon neoplasm. Acta Med Okayama. 50:1996;299-303.
120. Kusunoki T., Nishida S., Nakano T., et al. Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx. 22:1995;43-48.
121. Tumminello F.M., Leto G., Pizzolanti G., et al. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res. 16:1996;2315-2319.
122. Abecassis J., Collard R., Eber M., Pusel J., Fricker J.P., Methlin G. Proteinases and sialyltransferase in human breast tumors. Int J Cancer. 33:1984;821-824.
123. Warwas M., Haczynska H., Gerber J., Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem. 35:1997;301-304.
124. Sinha A.A., Gleason D.F., Limas C., et al. Localization of cathepsin B in normal and hyperplastic human prostate by immunoperoxidase and protein A-gold techniques. Anat Rec. 223:1989;266-275.
125. Xing R., Wu F., Mason R.W. Control of breast tumor cell growth using a targeted cysteine protease inhibitor. Cancer Res. 58:1998;904-909.
126. Pietras R.J., Szego C.M., Roberts J.A., Seeler B.J. Lysosomal cathepsin B-like activity: mobilization in prereplicative and neoplastic epithelial cells. J Histochem Cytochem. 29:1981;440-450.
127. Van Noorden C.J., Jonges T.G., Van Marle J., et al. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin Exp Metastasis. 16:1998;159-167.
128. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 11:1997;51-59.
129. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 271:1996;10079-10086.
130. Noel A., De Pauw-Gillet M.C., Purnell G., Nusgens B., Lapiere C.M., Foidart J.M. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer. 68:1993;909-915.
131. Noel A., Hajitou A., L'Hoir C., et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer. 76:1998;267-273.
132. Oursler M.J., Riggs B.L., Spelsberg T.C. Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells. Endocrinology. 133:1993;2187-2196.
133. Mooradian D.L., Lucas R.C., Weatherbee J.A., Furcht L.T. Transforming growth factor-beta 1 binds to immobilized fibronectin. J Cell Biochem. 41:1989;189-200.
134. Paralkar V.M., Vukicevic S., Reddi A.H. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol. 143:1991;303-308.
135. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:1992;65-71.
136. Sinha A.A., Gleason D.F., Staley N.A., Wilson M.J., Sameni M., Sloane B.F. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat Rec. 241:1995;353-362.
137. Mikkelsen T., Yan P.-S., Ho K.-L., Sameni M., Sloane B.F., Rosenblum M.R. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg. 83:1995;285-290.
138. Keppler D., Sameni M., Moin K., Mikkelsen T., Diglio C.A., Sloane B.F. Tumor progression and angiogenesis: cathepsin B & Co. Biochem Cell Biol. 74:1996;799-810.
139. Kuzuya M., Kinsella J.L. Reorganization of endothelial cord-like structures on basement membrane complex (Matrigel): involvement of transforming growth factor beta 1. J Cell Physiol. 161:1994;267-276.
140. Panchal R.G., Cusack E., Cheley S., Bayley H. Tumor protease-activated, pore-forming toxins from a combinatorial library. Nat Biotechnol. 14:1996;852-856.
141. Weissleder R., Tung C.H., Mahmood U., Bogdanov A. Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 17:1999;375-378.
142. Brown P.D. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 107:1999;174-180.
143. Koivunen E., Arap W., Valtanen H., et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 17:1999;768-774.
144. Mai J., Finley R., Waisman D.M., Sloane B.F., submitted.
145. Ahram M., Sameni M., Linebaugh B., Qiu R.-G., Kirn D., Sloane B.F., submitted.
146. Sameni M., Sloane B.F., submitted.